Skip to main content

Trospium Pregnancy and Breastfeeding Warnings

Brand names: Regurin, Sanctura, Sanctura XR

Medically reviewed by Drugs.com. Last updated on Aug 8, 2023.

Trospium Pregnancy Warnings

Animal studies have revealed no evidence of embryotoxicity or teratogenicity at doses up to 9 times the recommended human dose. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: C

See references

Trospium Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Yes (less than 1%)

Comments:
-The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. Product Information. Sanctura (trospium). Odyssey Pharmaceuticals.

References for breastfeeding information

  1. Product Information. Sanctura (trospium). Odyssey Pharmaceuticals.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer